Expand MRK Menu
MRK MENU

MRK Latest Press Releases

-- February 4, 2025 --

Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results Business Wire 6:30 AM

-- January 31, 2025 --

Merck Receives Positive EU CHMP Opinion for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults Business Wire 6:45 AM

-- January 30, 2025 --

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR (sotatercept-csrk) Early and Move to Final Analysis Business Wire 6:45 AM

-- January 28, 2025 --

Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase Authorization Business Wire 1:28 PM

-- January 27, 2025 --

FDA Grants Priority Review to Merck's Application for WELIREG (belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (PPGL) Business Wire 6:45 AM

-- January 24, 2025 --

Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma Business Wire 6:45 AM

-- January 16, 2025 --

Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4 Business Wire 6:45 AM

-- January 13, 2025 --

Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments Yolowire 9:18 AM

-- January 8, 2025 --

Merck's GARDASIL Receives Expanded Approval for Males in China Business Wire 6:48 AM

-- January 6, 2025 --

Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference Business Wire 6:45 AM

-- December 20, 2024 --

Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody Business Wire 6:45 AM

-- December 19, 2024 --

Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection Business Wire 6:45 AM

-- December 18, 2024 --

Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist Business Wire 6:45 AM

-- December 17, 2024 --

Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season Business Wire 6:45 AM

-- December 16, 2024 --

Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab Business Wire 4:30 PM
Merck's KEYTRUDA (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC Business Wire 6:45 AM

-- December 13, 2024 --

Merck Receives Positive EU CHMP Opinion for WELIREG (belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma Business Wire 7:05 AM

-- December 11, 2024 --

LYNPARZA (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial Business Wire 10:22 AM

-- December 9, 2024 --

Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer Business Wire 6:45 AM

-- December 8, 2024 --

Merck's Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma Business Wire 3:00 PM

-- December 5, 2024 --

Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults Business Wire 6:45 AM

-- December 3, 2024 --

FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations Business Wire 6:45 AM

-- November 26, 2024 --

Merck to Participate in the Citi 2024 Global Healthcare Conference Business Wire 6:45 AM

-- November 25, 2024 --

Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR (sotatercept-csrk) Met Primary Endpoint at Interim Analysis Business Wire 6:45 AM

-- November 22, 2024 --

Merck Recommends Rejection of TRC Capital's "Mini-Tender" Offer Business Wire 4:17 PM
Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference Business Wire 7:15 AM
Merck's WELIREG (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors Business Wire 6:45 AM
Surendralal Karsanbhai Elected to Merck Board of Directors Business Wire 6:30 AM

-- November 21, 2024 --

Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities Business Wire 6:45 AM

-- November 19, 2024 --

Merck Announces First-Quarter 2025 Dividend Business Wire 12:22 PM
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints Business Wire 6:45 AM

-- November 15, 2024 --

Merck Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM) Business Wire 7:15 AM

-- November 14, 2024 --

Merck to Participate in the Jefferies London Healthcare Conference Business Wire 7:15 AM
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd. Business Wire 6:45 AM

-- November 12, 2024 --

KOSELUGO (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial Business Wire 6:45 AM

-- November 7, 2024 --

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance Business Wire 7:00 AM

-- November 6, 2024 --

Merck to Participate in the UBS Global Healthcare Conference Business Wire 6:45 AM

-- October 31, 2024 --

Merck Announces Third-Quarter 2024 Financial Results Business Wire 6:30 AM

-- October 28, 2024 --

Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC) Business Wire 6:45 AM

-- October 24, 2024 --

Merck's KEYTRUDA (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers Business Wire 6:45 AM

-- October 23, 2024 --

CDC'S ACIP Recommends Merck's CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older Business Wire 7:58 PM

-- October 19, 2024 --

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 Business Wire 5:09 PM

-- October 17, 2024 --

Merck's Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants Business Wire 6:00 PM

-- October 16, 2024 --

Merck's CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease Business Wire 6:45 AM

-- October 14, 2024 --

Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG (belzutifan) in Renal Cell Carcinoma Business Wire 8:00 AM

-- October 9, 2024 --

New Data to be Presented at IDWeek 2024 Reinforce Merck's Broad and Diverse Vaccines and Infectious Disease Pipeline and Portfolio Business Wire 6:45 AM

-- October 8, 2024 --

Merck's KEYTRUDA (pembrolizumab) Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma Business Wire 6:45 AM

-- October 1, 2024 --

Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical Business Wire 6:45 AM
Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31 Business Wire 6:30 AM

-- September 26, 2024 --

Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024 Business Wire 6:45 AM

-- September 25, 2024 --

Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer Business Wire 6:45 AM
Merck's KEYTRUDA (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma Business Wire 6:30 AM

-- September 24, 2024 --

Merck Animal Health Announces Expansion of NOBIVAC NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus Business Wire 8:06 AM

-- September 20, 2024 --

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs Globe Newswire 9:00 AM
Merck Receives Positive EU CHMP Opinions for KEYTRUDA (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers Business Wire 7:30 AM

-- September 18, 2024 --

FDA Approves Merck's KEYTRUDA (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM) Business Wire 6:45 AM

-- September 17, 2024 --

Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial Business Wire 6:00 AM

-- September 16, 2024 --

PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch Business Wire 7:15 AM
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 Globe Newswire 7:00 AM

-- September 15, 2024 --

KEYTRUDA (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) Business Wire 10:30 AM
Ten-Year Data for Merck's KEYTRUDA (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma Business Wire 8:45 AM

-- September 14, 2024 --

KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma Business Wire 10:35 AM
Merck's KEYTRUDA (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer Business Wire 10:30 AM
KEYTRUDA (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma Business Wire 3:15 AM

-- September 11, 2024 --

Merck to Participate in the Bank of America 2024 Global Healthcare Conference Business Wire 6:45 AM
Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL9 in Japanese Males Business Wire 6:30 AM

-- September 10, 2024 --

Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives Yolowire 6:58 PM

-- September 7, 2024 --

Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial Business Wire 11:30 AM

-- September 4, 2024 --

Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024 Business Wire 6:45 AM
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret for the Treatment of Diabetic Macular Edema Business Wire 6:40 AM